The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study.In the 393-patient trial, drug candidate rezpegaldesleukin showed a reduction in the ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week ...

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the ...

An itchy scalp may be related to your hair-washing schedule, but may stem from various other causes, including skin ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...